Boehringer, Lilly’s Jardiance ties to match AZ’s Farxiga with heart failure labelBoehringer and Eli Lilly have moved closer to a heart failure indication for their SGLT2 inhibitor Jardiance, as Share XBoehringer, Lilly’s Jardiance ties to match AZ’s Farxiga with heart failure labelhttps://pharmaphorum.com/news/boehringer-lillys-jardiance-ties-to-match-azs-farxiga-with-heart-failure-label/
NICE backs AZ’s Forxiga for heart failureJust a few weeks after its EU approval for heart failure, AstraZeneca’s Forxiga has been backed by NICE Share XNICE backs AZ’s Forxiga for heart failurehttps://pharmaphorum.com/news/nice-backs-azs-forxiga-for-heart-failure/
Entresto set for big sales hike after FDA panel endorsementNovartis’ Entresto is on course to become the first drug to be approved in the US for a Share XEntresto set for big sales hike after FDA panel endorsementhttps://pharmaphorum.com/news/entresto-set-for-big-sales-hike-after-fda-panel-endorsement/
AZ’s Q3 results disappoint – but COVID-19 vaccine trial is still on trackAstraZeneca has posted an uninspiring set of quarterly results as it gears up for results from its closely Share XAZ’s Q3 results disappoint – but COVID-19 vaccine trial is still on trackhttps://pharmaphorum.com/news/azs-q3-results-disappoint-but-covid19-vaccine-trial-is-still-on-track/
Boehringer, Yale trial digital tech in heart failurePatients with heart failure often have a dismal prognosis as the condition usually worsens over time, but a Share XBoehringer, Yale trial digital tech in heart failurehttps://pharmaphorum.com/news/boehringer-yale-trial-digital-tech-in-heart-failure/
Amgen shares down as heart failure drug disappoints in phase 3 trialShares in Amgen were down nearly 7% after close of trading yesterday after the company’s heart failure drug Share XAmgen shares down as heart failure drug disappoints in phase 3 trialhttps://pharmaphorum.com/news/amgen-shares-down-7-after-heart-failure-drug-disappoints-in-phase-3-trial/
Study puts Jardiance in hot pursuit of AZ’s Farxiga in heart failureThe FDA’s approval of AstraZeneca’s SGLT2 inhibitor Farxiga in heart failure was a first for the class, but Share XStudy puts Jardiance in hot pursuit of AZ’s Farxiga in heart failurehttps://pharmaphorum.com/news/study-puts-jardiance-in-hot-pursuit-of-azs-farxiga-in-heart-failure/
FDA grants fast review for Bayer/Merck & Co’s heart failure drugThe FDA has granted a faster Priority Review for Bayer and Merck & Co’s filing for vericiguat, which is being Share XFDA grants fast review for Bayer/Merck & Co’s heart failure drughttps://pharmaphorum.com/news/fda-grants-fast-review-for-bayer-merck-cos-heart-failure-drug/
FDA approves new heart failure use for AZ’s FarxigaThe FDA has approved a new use for AstraZeneca’s Farxiga (dapagliflozin) to reduce risk of cardiovascular death and hospitalisation with heart failure, in Share XFDA approves new heart failure use for AZ’s Farxigahttps://pharmaphorum.com/news/fda-approves-new-heart-failure-use-for-azs-farxiga/
